Physician profile
Albert E Scates
NPI 1700923679
$2,309.06
in general payments reported to CMS, 2019-2025
13 companies · $685 in 2025
The $685 reported for 2025 was more than what 98% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $377 · 2022: $453 · 2023: $391 · 2024: $403 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,007.17 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $515.21 | 2022-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $213.23 | 2022-2025 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $199.02 | 2022-2024 | Ocaliva |
| Madrigal Pharmaceuticals | $142.81 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.80 | 2022-2025 | Xifaxan |
| Braintree Laboratories, INC. | $48.70 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $34.97 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $29.67 | 2023-2024 | Dificid |
| Redhill Biopharma INC. | $18.96 | 2021 | |
| Mauna Kea Technologies, INC. | $17.34 | 2024 | |
| Ardelyx, INC. | $15.84 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $14.34 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Scates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.